Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42(14):2212–2221. doi:10.1016/j.ejca.2006.04.012
   PubMed Web of Science ®Google Scholar
• Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301. doi:10.2147/CLEP.S34285
   PubMedGoogle Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–359. doi:10.6004/jnccn.2021.0012
   PubMed Web of Science ®Google Scholar
• Dong C, Ding Y, Weng S, et al. Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020. Chin J Cancer Res. 2021;33(3):302–307. doi:10.21147/j.issn.1000-9604.2021.03.02
   PubMed Web of Science ®Google Scholar
• Kim JJ, Kang J, Hong YS, et al. Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment. Med Oncol. 2018;35(5):65. doi:10.1007/s12032-018-1124-5
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet. 2013;381(9863):303–312. doi:10.1016/S0140-6736(12)61900-X
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–629. doi:10.1016/S1470-2045(15)70156-7
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018;319(24):2486–2496. doi:10.1001/jama.2018.7855
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of Tas-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–1919. doi:10.1056/NEJMoa1414325
   PubMed Web of Science ®Google Scholar
• Xu J, Kim TW, Shen L, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (Tas-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018;36(4):350–358. doi:10.1200/JCO.2017.74.3245
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Yilmaz M, Möller S, et al. Tas-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, Phase 2 trial. Lancet Oncol. 2020;21(3):412–420. doi:10.1016/S1470-2045(19)30827-7
   PubMed Web of Science ®Google Scholar
• Kuboki Y, Nishina T, Shinozaki E, et al. Tas-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, Phase 1/2 study. Lancet Oncol. 2017;18(9):1172–1181. doi:10.1016/S1470-2045(17)30425-4
   PubMed Web of Science ®Google Scholar
• Satake H, Kato T, Oba K, et al. Phase Ib/II study of Biweekly Tas-102 in combination with bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (BiTS Study). Oncologist. 2020;25(12):e1855–e1863. doi:10.1634/theoncologist.2020-0643
   PubMed Web of Science ®Google Scholar
• Tabernero J, Taieb J, Prager GW, et al. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Future Oncol. 2021;17(16):1977–1985. doi:10.2217/fon-2020-1238
   PubMed Web of Science ®Google Scholar
• Cremolini C, Rossini D, Dell’Aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5(3):343–350. doi:10.1001/jamaoncol.2018.5080
   PubMed Web of Science ®Google Scholar
• Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38(18):2053–2061. doi:10.1200/JCO.19.03296
   PubMed Web of Science ®Google Scholar
• Fakih M, Singh Raghav KP, Chang DZ, et al. Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC); 2021. Available from: doi:10.1200/JCO.2021.39.15_suppl.3560. Accessed February 10, 2023.
   Google Scholar
• Kim RD, Kovari BP, Martinez M, et al. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022;169:93–102. doi:10.1016/j.ejca.2022.03.026
   PubMed Web of Science ®Google Scholar
• Cousin S, Cantarel C, Guegan JP, et al. Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial. Clin Cancer Res. 2021;27(8):2139–2147. doi:10.1158/1078-0432.CCR-20-3416
   PubMed Web of Science ®Google Scholar
• Wang F, He MM, Yao YC, et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Cell Rep Med. 2021;2(9):100383. doi:10.1016/j.xcrm.2021.100383
   PubMedGoogle Scholar
• Yao Y, Jin Y, Wang M, et al. P-170 Exploratory biomarker findings from regorafenib plus toripalimab in patients with refractory metastatic colorectal cancer (REGOTORI study); 2022. Available from: https://www.annalsofoncology.org/article/S0923-7534(22)00950-4/fulltext. Accessed February 10, 2023.
   Google Scholar
• Gomez-Roca C, Yanez E, Im SA, et al. LEAP-005: a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—results from the colorectal cancer cohort; 2021. Available from: 10.1200/JCO.2021.39.3_suppl.94. Accessed February 10, 2023.
   Google Scholar
• Xiao L, Zhang Y, Lin Q. 442P - Camrelizumab combined with apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer: one-arm exploratory clinical trial; 2020. Available from: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/camrelizumab-combined-with-apatinib-in-the-treatment-of-patients-with-advanced-gastric-cancer-and-colorectal-cancer-one-arm-exploratory-clinical-t. Accessed February 10, 2023.
   Google Scholar
• Gou M, Yan H, Liu Tie E, et al. Fruquintinib combination with sintilimab in refractory metastatic colorectal cancer patients in China; 2020. Available from: 10.1200/JCO.2020.38.15_suppl.4028. Accessed February 10, 2023.
   Google Scholar
• Guo Y, Zhang W, Ying J, et al. Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer; 2021. Available from: 10.1200/JCO.2021.39.15_suppl.2514. Accessed February 10, 2023.
   Google Scholar
• Bai Y, Xu N, An S, Chen W, Gao C, Zhang D. A phase Ib trial of assessing the safety and preliminary efficacy of a combination therapy of geptanolimab (GB 226) plus fruquintinib in patients with metastatic colorectal cancer (mCRC); 2021. Available from: 10.1200/JCO.2021.39.15_suppl.e15551. Accessed February 10, 2023.
   Google Scholar
• Sato A, Kurihara M, Horikoshi N, et al. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group. Anticancer Drugs. 1999;10(8):741–748. doi:10.1097/00001813-199909000-00008
   PubMed Web of Science ®Google Scholar
• Jackman AL, Kimbell R, Ford HE. Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations. Eur J Cancer. 1999;35(Suppl 1):S3–8. doi:10.1016/S0959-8049(99)00041-6
   PubMedGoogle Scholar
• Jackman AL, Farrugia DC, Gibson W, et al. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer. 1995;31a(7–8):1277–1282. doi:10.1016/0959-8049(95)00166-G
   PubMed Web of Science ®Google Scholar
• Jeung HC, Rha SY, Cho BC, et al. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer. 2006;95(12):1637–1641. doi:10.1038/sj.bjc.6603468
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Taniguchi H, Komori A, et al. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. BMC Cancer. 2015;15:601. doi:10.1186/s12885-015-1606-1
   PubMed Web of Science ®Google Scholar
• Yoshida M, Takagane A, Miyake Y, et al. A phase II study of third-line combination chemotherapy with bevacizumab plus S-1 for metastatic colorectal cancer with mutated KRAS (SAVIOR study). Oncology. 2016;91(1):24–30. doi:10.1159/000446372
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu J, Cheng K, et al. S-1 plus raltitrexed for refractory metastatic colorectal cancer: a phase II trial. Oncologist. 2019;24(5):591–e165. doi:10.1634/theoncologist.2018-0901
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhou YW, Cheng K, et al. Bevacizumab combined with S-1 and raltitrexed for patients with metastatic colorectal cancer refractory to standard therapies: a phase II study. Oncologist. 2021;26(8):e1320–e1326. doi:10.1002/onco.13778
   PubMed Web of Science ®Google Scholar
• Shibutani M, Nagahara H, Fukuoka T, et al. Combining bevacizumab with trifluridine/thymidine phosphorylase inhibitor improves the survival outcomes regardless of the usage history of bevacizumab in front-line treatment of patients with metastatic colorectal cancer. Anticancer Res. 2020;40(7):4157–4163. doi:10.21873/anticanres.14415
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37. doi:10.1016/S1470-2045(12)70477-1
   PubMed Web of Science ®Google Scholar
• Masi G, Salvatore L, Boni L, et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol. 2015;26(4):724–730. doi:10.1093/annonc/mdv012
   PubMed Web of Science ®Google Scholar
• Hecht JR, Cohn A, Dakhil S, et al. SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer. 2015;14(2):72–80. doi:10.1016/j.clcc.2014.12.009
   PubMed Web of Science ®Google Scholar
• Bennouna J, Hiret S, Bertaut A, et al. Continuation of bevacizumab vs cetuximab plus chemotherapy after first progression in KRAS wild-type metastatic colorectal cancer: the UNICANCER PRODIGE18 randomized clinical trial. JAMA Oncol. 2019;5(1):83–90. doi:10.1001/jamaoncol.2018.4465
   PubMed Web of Science ®Google Scholar
• Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87–98. doi:10.1016/j.ejca.2016.10.007
   PubMed Web of Science ®Google Scholar
• Meng Q, Zheng N, Wen R, Sui J, Zhang W. Preoperative nomogram to predict survival following colorectal cancer liver metastasis simultaneous resection. J Gastrointest Oncol. 2021;12(2):556–567. doi:10.21037/jgo-20-329
   PubMed Web of Science ®Google Scholar
• Lehtomäki K, Mustonen H, Kellokumpu-Lehtinen PL, et al. Lead time and prognostic role of serum CEA, CA19-9, IL-6, CRP, and YKL-40 after adjuvant chemotherapy in colorectal cancer. Cancers. 2021;13(15):3892. doi:10.3390/cancers13153892
   PubMed Web of Science ®Google Scholar
• Guo X, Liu Y, Liu LJ, et al. Development and validation of survival nomograms in colorectal cancer patients with synchronous liver metastases underwent simultaneous surgical treatment of primary and metastatic lesions. Am J Cancer Res. 2021;11(6):2654–2669.
   PubMed Web of Science ®Google Scholar
• Stillwell AP, Ho YH, Veitch C. Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg. 2011;35(3):684–692. doi:10.1007/s00268-010-0891-8
   PubMed Web of Science ®Google Scholar
• Kuramochi H, Yamada T, Yoshida Y, et al. The pre-treatment lymphocyte-to-monocyte ratio predicts efficacy in metastatic colorectal cancer treated with Tas-102 and bevacizumab. Anticancer Res. 2021;41(6):3131–3137. doi:10.21873/anticanres.15098
   PubMed Web of Science ®Google Scholar